Medicare Issues Final Coverage Determination for kidneyintelX.dkd

June 14, 2024

https://www.globenewswire.com/news-release/2024/06/14/2898900/0/en/Medicare-Issues-Final-Coverage-Determination-for-kidneyintelX-dkd.html

LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ:RNLX) (LSE:RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination (“LCD”) for the Company’s kidneyintelX.dkd testing. The final LCD can be accessed at LCD – KidneyIntelX and KidneyIntelX.dkd Testing (L39726) (cms.gov), and is effective for dates of service on or after August 1, 2024. The established Medicare price for kidneyintelX.dkd is $950 per test. Distinct CPT Codes (Common Procedural Terminology Codes) have been established for kidneyintelX.dkd and is published in CMS’ 2024 Clinical Lab Fee Schedule.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.